Immunocore Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Bahija Jallal

İcra Kurulu Başkanı

US$11.7m

Toplam tazminat

CEO maaş yüzdesi	6.3%
CEO görev süresi	5.8yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	5.2yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Bahija Jallal'un ücretlendirmesi Immunocore Holdings'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$47m
Jun 30 2024	n/a	n/a	-US$55m
Mar 31 2024	n/a	n/a	-US$60m
Dec 31 2023	US$12m	US$735k	-US$55m
Sep 30 2023	n/a	n/a	-US$69m
Jun 30 2023	n/a	n/a	-US$61m
Mar 31 2023	n/a	n/a	-US$52m
Dec 31 2022	US$1m	US$700k	-US$53m
Sep 30 2022	n/a	n/a	-US$62m
Jun 30 2022	n/a	n/a	-US$112m
Mar 31 2022	n/a	n/a	-US$156m
Dec 31 2021	US$35m	US$700k	-US$180m
Sep 30 2021	n/a	n/a	-US$150m
Jun 30 2021	n/a	n/a	-US$139m
Mar 31 2021	n/a	n/a	-US$116m
Dec 31 2020	US$1m	n/a	-US$101m

Tazminat ve Piyasa: Bahija 'nin toplam tazminatı ($USD 11.68M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.64M ).

Tazminat ve Kazançlar: Bahija şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Bahija Jallal (63 yo)

5.8yrs

Görev süresi

US$11,678,834

Tazminat

Dr. Bahija Jallal, Ph.D. serves as Director of Outpace Bio, Inc. from March 2023. She serves as Chief Executive Officer and Director of Immunocore Holdings plc (formerly known as Immunocore Holdings Limite...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Bahija Jallal	CEO & Executive Director	5.8yrs	US$11.68m	Veri yok
Brian Di Donato	Executive VP	4.6yrs	US$3.35m	0.038% € 601.8k
Tina Leger	Chief Human Resources Officer	2.8yrs	US$1.04m	Veri yok
David Berman	Executive Vice President of Research & Development	5.8yrs	US$4.40m	0% € 0
John Trainer	SVP & Chief Operating Officer	less than a year	Veri yok	Veri yok
John Goll	SVP, Finance & Chief Accounting Officer	less than a year	Veri yok	Veri yok
Annelise Vuidepot	Senior VP	no data	Veri yok	Veri yok
Sean Buckley	VP & Chief Information Officer	less than a year	Veri yok	Veri yok
Clayton Robertson	Head of Investor Relations	no data	Veri yok	Veri yok
Lily Hepworth	Senior VP	3.8yrs	Veri yok	Veri yok
Elizabeth Jobes	Chief Compliance Officer	less than a year	Veri yok	Veri yok
Sébastien Desprez	Vice President of Communications	2.8yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim: 6YG 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Bahija Jallal	CEO & Executive Director	5.8yrs	US$11.68m	Veri yok
John Bell	Independent Non-Executive Chairman	9.7yrs	US$416.99k	0.027% € 421.1k
Kristine Peterson	Independent Non-Executive Director	7yrs	US$389.49k	0% € 0
Robert Perez	Independent Non-Executive Director	5.2yrs	Veri yok	Veri yok
Roy Steven Herbst	Independent Non-Executive Director	3.8yrs	US$386.99k	0% € 0
Peter Ratcliffe	Independent Non-Executive Director	4yrs	US$384.49k	0.00067% € 10.5k
Ranjeev Krishana	Director	less than a year	Veri yok	Veri yok
Travis Coy	Independent Non-Executive Director	5.2yrs	Veri yok	Veri yok
Siddharth Kaul	Independent Non-Executive Director	2.4yrs	US$386.99k	0% € 0

5.2yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 6YG 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.2 yıldır).

Immunocore Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Immunocore Holdings plc Announces Brian Di Donato Plans to Leave At the End of the Year as Chief Financial Officer

Immunocore Holdings plc Appoints Ranjeev Krishana to Serve as A Class I Director

Insufficient new directors

Immunocore Holdings plc, Annual General Meeting, May 23, 2024

High number of new directors

High number of new directors

Recent updates

Third quarter 2024 earnings released: EPS: US$0.17 (vs US$0.018 in 3Q 2023)

New major risk - Revenue and earnings growth

Immunocore Presents Phase 1 Data of Brenetafusp, an Immtac Bispecific Targeting Prame, in Patients with Ovarian Cancer

Immunocore Holdings plc Announces Brian Di Donato Plans to Leave At the End of the Year as Chief Financial Officer

Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.35 loss in 2Q 2023)

Immunocore Holdings plc to Report Q2, 2024 Results on Aug 08, 2024

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Immunocore Holdings plc Announces Randomization of First Patient in the Global, Registrational Phase 3 Clinical Trial Testing Brenetafusp for the Treatment of First-Line Advanced or Metastatic Cutaneous Melanoma

Immunocore Holdings plc Presents KIMMTRAK Clinical Data Demonstrating That Patients with Stable Disease and Confirms Tumor Reduction Have Similar Clinical Outcomes to Patients with Partial Response

Immunocore Holdings plc Appoints Ranjeev Krishana to Serve as A Class I Director

Immunocore Holdings plc Converts Phase 2/3 TEBE-AM Clinical Trial into Registrational Phase 3 Trial Evaluating KIMMTRAK for Previously Treated Advanced Cutaneous Melanoma

Now 22% undervalued after recent price drop

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.49 loss per share (vs US$0.43 loss in 1Q 2023)

Insufficient new directors

Immunocore Holdings plc, Annual General Meeting, May 23, 2024

Full year 2023 earnings released: US$1.13 loss per share (vs US$1.09 loss in FY 2022)

Immunocore Holdings plc to Report Q4, 2023 Results on Feb 28, 2024

Immunocore Holdings plc Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2023

Immunocore Holdings plc Announces the Addition of Two New Pre-Clinical Candidates for Autoimmune Diseases to Its Pipeline

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: UK£0.04 (vs UK£0.13 in 3Q 2022)

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: UK£0.29 loss per share (vs UK£0.14 loss in 2Q 2022)

Immunocore Holdings plc to Report Q2, 2023 Results on Aug 10, 2023

First quarter 2023 earnings released: UK£0.35 loss per share (vs UK£0.37 loss in 1Q 2022)

Forecast breakeven date moved forward to 2024

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: UK£0.90 loss per share (vs UK£3.10 loss in FY 2021)

Immunocore Holdings plc Provides Revenue Guidance for the Fourth Quarter and Twelve Months Ended December 31, 2022

Immunocore Holdings plc Announces the Addition of Three New ImmTAC Product Candidates

Forecast to breakeven in 2025

Immunocore Holdings plc Presents Ovarian Cancer Expansion Data for ImmTAC® candidate IMC-C103C targeting MAGE-A4

An unknown buyer acquired a 5% stake in Immunocore Holdings plc (NasdaqGS:IMCR) from Malin Corporation plc (ISE:MLC) for approximately €150 million.

Third quarter 2022 earnings released: EPS: UK£0.13 (vs UK£0.69 loss in 3Q 2021)

High number of new directors

Second quarter 2022 earnings released

Immunocore Holdings plc to Report Q2, 2022 Results on Aug 10, 2022

High number of new directors

Immunocore Holdings plc announced that it has received $139.999988 million in funding from RTW Investments, LP, Rock Springs Capital Management LP, General Atlantic Service Company, L.P., Baker Bros. Advisors LP and another investor

Immunocore Holdings plc announced that it expects to receive $139.999988 million in funding from RTW Investments, LP, Rock Springs Capital Management LP, General Atlantic Service Company, L.P.

Immunocore Announces Dosing of First Patient with ImmTAV(R) Bispecific for HIV

High number of new directors

Immunocore Announces the Presentation of Initial Data from the Phase 1 Immtav® Trial for Chronic Hepatitis B At the EASL International Liver Congress™

Immunocore Holdings plc Appoints Siddharth (Sid) Kaul as A Non-Executive Member of Its Board of Directors

Immunocore Holdings plc Announces UK Medicines and Healthcare Products Regulatory Agency, Australian Therapeutic Goods Administration and Health Canada Approves Kimmtrak® (Tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma

Immunocore Holdings plc Presents New Data on KIMMTRAK (tebentafusp-tebn) in metastatic Cutaneous Melanoma (mCM) and metastatic Uveal Melanoma (mUM) at the 2022 American Society of Clinical Oncology Annual Meeting

Immunocore Announces Upcoming Presentations At the 2022 American Society of Clinical Oncology Annual Meeting

First quarter 2022 earnings released: UK£0.37 loss per share (vs UK£0.76 loss in 1Q 2021)

Immunocore Holdings plc, Annual General Meeting, May 12, 2022

European Commission Approves Immunocore Holdings plc's KIMMTRAK (Tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Immunocore Holdings plc Receives Positive CHMP Opinion for KIMMTRAK (Tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma

Immunocore Holdings plc Announces Approval from the United States Food and Drug Administration of KIMMTRAK for the Treatment of Unresectable or Metastatic Uveal Melanoma

Third quarter 2021 earnings released: UK£0.69 loss per share (vs UK£0.064 loss in 3Q 2020)

Immunocore Announces Publication of Phase 3 Data Comparing tebentafusp with Investigator’s Choice in the New England Journal of Medicine

Immunocore Presents Data At the European Society for Medical Oncology (Esmo) Congress 2021 Demonstrating A Reduction in Circulating Tumor DNA (ctDNA) While on Tebentafusp Is Associated with Overall Survival in the Phase 2 Clinical Trial

Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

An unknown buyer acquired stake in Immunocore Holdings plc (NasdaqGS:IMCR) from Medigene AG (XTRA:MDG1) for $4.7 million.

Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

Second quarter 2021 earnings released: UK£0.75 loss per share (vs UK£0.63 loss in 2Q 2020)

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş